GW Pharmaceuticals PLC Notice of Q4 and year-end results (4818Q)
November 30 2016 - 8:00AM
UK Regulatory
TIDMGWP
RNS Number : 4818Q
GW Pharmaceuticals PLC
30 November 2016
GW Pharmaceuticals to Report Q4 and Year-End Financial Results
and Host Conference Call on 5 December, 2016
London, UK, 30 Nov 2016: GW Pharmaceuticals plc (Nasdaq: GWPH,
AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
will announce on 5 December, 2016 its fourth quarter and year-end
financial results for the period ending 30 September, 2016. GW will
also host a conference call the same day at 8:00 a.m. EST (1:00
p.m. GMT). Conference call information will be provided in the
financial results press release. A replay of the call will also be
available through the Company's website (www.gwpharm.com) shortly
after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW is advancing an orphan drug program in the field
of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol),
which is in Phase 3 clinical development for the treatment of
Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis
Complex and Infantile Spasms. GW commercialized the world's first
plant-derived cannabinoid prescription drug, Sativex(R) , which is
approved for the treatment of spasticity due to multiple sclerosis
in 30 countries outside the United States. The Company has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for glioma,
schizophrenia and epilepsy. For further information, please visit
www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor 917 280 2424 / 401 500
Relations (U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway +44 20 3727 1000
Peel Hunt LLP (UK NOMAD)
James Steel +44 20 7418 8900
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORUKAKRNNAAUAA
(END) Dow Jones Newswires
November 30, 2016 08:00 ET (13:00 GMT)
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Dec 2023 to Dec 2024